The anti-cancer drug durvalumab used in immunotherapy delivers a 66-month survival breakthrough for lung cancer patients, ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical study.

Patients with advanced bladder cancer have significantly less risk of the disease progressing or returning when treated with an immunotherapy drug called durvalumab, research has shown. Jörg ...

The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable gastric or gastroesophageal junction cancer, the agency announced on Tuesday.

HOUSTON -- Patients with advanced or refractory cutaneous T-cell lymphoma (CTCL) achieved near-100% disease control with single-agent immunotherapy or an immuno-oncology (IO) combination, a small ...

For many cases of gastric (stomach) or gastroesophageal (GEJ) cancer, the standard treatment involves surgical removal of the malignant tissue, along with perioperative chemotherapy. Patients ...